These Analysts Boost Their Forecasts On Vir Biotechnology

Core Insights - Vir Biotechnology reported a fourth-quarter loss of 31 cents, which was better than the consensus loss of 41 cents, with sales reaching $64.07 million, significantly surpassing the consensus of $23.18 million [1] - The company announced a partnership with a Japanese drugmaker to advance VIR-5500, an investigational treatment for prostate cancer, enhancing its oncology pipeline [1] Financial Performance - The fourth-quarter loss was 31 cents, beating the expected loss of 41 cents [1] - Sales for the quarter were $64.07 million, exceeding the consensus estimate of $23.18 million [1] Clinical Development - New data from the ongoing Phase 1 trial of VIR-5500 for advanced metastatic castration-resistant prostate cancer (mCRPC) patients was shared, indicating progress in the treatment area [2] - The stock price increased by 30.3% to $9.68 following the announcements [2] Analyst Ratings - Needham analyst Joseph Stringer maintained a Buy rating and raised the price target from $14 to $18 [3] - Evercore ISI Group analyst Cory Kasimov maintained an Outperform rating and increased the price target from $12 to $18 [3] - Morgan Stanley analyst Michelle Gilson maintained an Overweight rating and raised the price target from $20 to $24 [3]